Diabetes technology should be matched to a person’s needs, abilities, preferences and life circumstances, and introduced early when appropriate, according to a peer-reviewed practice review. The authors say this can include implementation at diagnosis. The review’s stated task was to examine when modern technologies are indicated, what clinical benefits they may offer, and what safety considerations matter in routine care.
The article brings together current guidelines, position papers, randomized controlled trials, meta-analyses and selected real-world data. It does not report a newly enrolled participant group: the authors state that no human or animal studies were conducted for this contribution. The result is a practice-oriented synthesis of existing evidence, not a new participant-level study.
Different tools, different roles
Continuous glucose monitoring, or CGM, is presented as support for people receiving insulin therapy, for those at significant risk of hypoglycemia, and in situations where CGM data can improve clinical decision-making. The review places CGM among tools whose use is tied to individual needs and circumstances.
For type 1 diabetes, the review describes automated insulin delivery systems, or AID, as the preferred choice. For people with type 2 diabetes receiving intensive insulin therapy, it describes AID as an effective therapeutic option. The two statements are population-specific and do not amount to a claim that every person with diabetes should use the same system.
Connected insulin pens have a narrower but useful role in the review. They are presented as tools that facilitate documentation and allow glucose and insulin data to be reviewed together. The article presents their value in terms of bringing those two kinds of information into the same clinical review.
Technology comes with conditions
Technology alone is not treated as the whole story. Regular training, standardized review of the data and a back-up plan are stated as required. In the authors’ interpretation, implementation includes teaching people how to use the system, examining its data consistently and maintaining an alternative plan.
That practical emphasis extends to hospital care. Patients may continue using their own diabetes devices in hospital when doing so is clinically appropriate and institutional processes are in place. The review makes that continuation conditional, rather than presenting patient-owned devices as suitable in every hospital.
Looking ahead, the review identifies three development goals: reducing the burden on users, improving interoperability between systems and increasing time in range, or TIR, the amount of time glucose remains within the target range. These are future aims, not outcomes reported as achieved in this contribution.
A practice summary, not a new trial
Because the article is a synthesis, it does not give readers a single effect size for any technology. The supplied analysis reports no quantitative pooled estimate for this contribution, and no newly enrolled sample or causal comparison is presented. The evidence base includes several study types, so the conclusions should be read as practice guidance rather than as a measured result from one trial.
Questions remain about which people with type 2 diabetes receiving intensive insulin therapy benefit most from AID, and how training, standardized data review, back-up planning and interoperability can be implemented reliably. The analysis also identifies the need to test whether lower user burden and better interoperability lead to better patient-important outcomes. These remain open questions, not settled findings.
The individual findings behind each recommendation would need to be examined to judge how strong and widely applicable the conclusions are. The review is best read as a high-level practice summary of indications and implementation issues, rather than as a basis for choosing a particular treatment or setting hospital policy on its own.
The peer-reviewed article was published on 21 August 2026. The authors report no funding and no conflict of interest, and say all data underlying the work are contained in the article.
Paper data and sources
Original title: [Continuous glucose monitoring and automated insulin dosing systems in clinical routine].
Authors: Annie Mathew, Dagmar Führer
Journal/Repository: Innere Medizin (Heidelberg, Germany)
Status: Peer-reviewed
First online: 2026-08-21
DOI: 10.1007/s00108-026-02166-6
Original paper · Full text